Chemical formula: C₈H₁₂N₄O₅ Molecular mass: 244.205 g/mol PubChem compound: 9444
Azacitidine is believed to exert its antineoplastic effects by multiple mechanisms including cytotoxicity on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA. The cytotoxic effects of azacitidine may result from multiple mechanisms, including inhibition of DNA, RNA and protein synthesis, incorporation into RNA and DNA, and activation of DNA damage pathways.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01BC07 | Azacitidine | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BC Pyrimidine analogues |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| VIDAZA Powder for suspension for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ONUREG Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Azacitidine is an active ingredient of these brands:
Australia (AU)Austria (AT)Canada (CA)Cyprus (CY)Ecuador (EC)Finland (FI)Italy (IT)Japan (JP)Mexico (MX)Netherlands (NL)New Zealand (NZ)South Africa (ZA)Spain (ES)Tunisia (TN)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
